SWOG clinical trial number
SWOG-8925
Evaluations of Cisplatin + VP-16 Followed by Mitotane at Progression if No Prior Mitotane or Cisplatin + VP-16 Only if Prior Treatment with Mitotane in Advanced and Metastatic Adrenal Cortical Carcinoma
Closed
Phase
Accrual
100%
Published
Abbreviated Title
Evaluations of Cisplatin + VP-16 Followed by Mitotane at Progression if No Prior Mitotane or Cisplatin + VP-16 Only if Prior Treatment with Mitotane in Advanced and Metastatic Adrenal Cortical…
Activated
06/15/1989
Closed
12/01/1995
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
2000
Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group study
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase